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Background: Recently, studies suggesting that vitamin D deficiency correlates with the severity and frequency of
Type 1 (insulin-dependent) diabetes mellitus (T1DM) and that vitamin D supplementation reduces the risk of
developing T1DM have been reported.
Objective: In this study, we aimed to assess vitamin D status in Egyptian children and adolescents with T1DM.
Methods: This was a case–control study including 80 T1DM diagnosed cases aged 6 to 16 years and 40 healthy
children with comparable age and gender as the control group. For all subjects, serum 25 (OH) D levels were
measured by ELISA, Serum parathyroid hormone (PTH) and serum insulin were measured by an
electrochemiluminesce immunoassay. Serum glucose, Glycosylated hemoglobin (HbA1c) levels and homeostasis
model assessment of insulin resistance (HOMA-IR) were also assessed.
Results: Compared to the control group, serum vitamin D levels were not significantly lower in diabetic subjects
(24.7 ± 5.6 vs 26.5 ± 4.8 ng/ml; P > 0.05). Among diabetic cases 44(55%) were vitamin D deficient; meanwhile 36
(45%) cases had normal vitamin D level (P < 0.01). In addition, 26(32.5%) diabetic cases had 2ry hyperparathyroidism
and 54(67.5%) cases had normal parathyroid hormone level; meanwhile, none of the control group had 2ry
hyperparathyroidism (P < 0.01). Furthermore, we found a significant difference between vitamin D deficient diabetic
cases and those with normal vitamin D level as regards HOMA-IR and diabetes duration (P < 0.01).
Conclusion: Public health message on the importance of vitamin D status; especially in diabetic children and
adolescents, should be disseminated to the public.
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Type 1 (insulin-dependent) diabetes mellitus (T1DM) is
an auto immune disease that results in the destruction
of beta cells in the pancreas as a result of interactions
between different susceptibility genes and environmental
exposures [1].
Peak incidence occurs around puberty, and the disease
is usually diagnosed before age 30. It is estimated that,
by the time the DM1 is diagnosed, 80–90% of the beta
cells are lost [2].
Recent studies suggest that vitamin D deficiency may
increase the risk of developing autoimmune diseases* Correspondence: Seham_Azab@yahoo.com
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stated.including type 1 diabetes (T1DM) [3,4]. This occurs
partly through loss of vitamin D modulation of the
immune and inflammatory reaction in diabetes [5].
At the level of the immune system, 1, 25(OH)2 D3 in-
hibits the differentiation and maturation of dendritic
cells and promotes their apoptosis [6], thus preventing
their transformation into antigen presenting cells which is
the first step in the initiation of an immune response [7].
At the level of the pancreatic islets, 1,25(OH)2D3 decreased
in vivo and in vitro proinflammatory chemokine and
cytokine expression (e.g., IL6), which are implicated in the
pathogenesis of T1DM making β-cells less chemoattractive
and less prone to inflammation; this results in decreased T
cell recruitment and infiltration, increased regulatory cells,
and arrest of the autoimmune process [8].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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variable prevalence of vitamin D deficiency ranging
from 15 to 60% among children and adolescents with
T1DM [9,10].
Before conducting a clinical trial of supplementing
patients with T1DM, it is required to assess the existing
status. In this study, we aimed to estimate vitamin D status
in Egyptian children and adolescents with T1DM.Methods
This was a case control study performed in Zagazig
University hospital from January to December 2012. The
study included 80 children and adolescents diagnosed as
T1DM cases (34 males and 46 females) while attending
Pediatric outpatient endocrine clinic in Zagazig University
Hospital. The age of the patients ranged from 6 to 16 years
(mean, 11.4 years). Forty healthy children of comparable
age and gender served as a control group. Subjects were
excluded from the study if they had consumed cholecalcif-
erol, calcium, multi-vitamin or mineral supplementation,
vitamin D-fortified foods during the previous 3 months,
or any medical co-morbidities or any other major chronic
disease.
All patients and controls included were subjected to
proper history taking, thorough clinical examination.
Including anthropometric measurements (weight, height
and BMI). Body Mass Index (BMI) was calculated as
follows: BMI = weight (kg)/height (m)2.
In all participants, and patients with BMI of more than
30 were considered obese according to the World Health
Organization classification [11]. Routine biochemical
investigations included serum calcium, phosphorus, alkaline
phosphatase (ALP), albumin, urea, and creatinine.Abnormal glucose homoeostasis
Criteria were defined under modified WHO criteria
adapted for children [12]. The impaired glucose tolerance
value is 2-h blood glucose (2 h. BG) _140 (7.8 mmol/l)
and <200 mg/dl (11.1 mmol/l) for OGTT, and _110 mg/dl
and <126 mg/dl for fasting glucose. For defined dia-
betes, the value is 2 h. BG >200 mg/dl for OGTT and/
or >126 mg/dl for fasting glucose [12].
Homeostasis model for assessment of insulin resistance
(HOMA-IR) is a convenient and beneficial method for
evaluating insulin resistance, especially in obese subjects,
and reflects insulin resistance obtained by euglycaemic
clamp more accurately than fasting plasma insulin levels
alone. It was calculated with the following formula
(HOMA-IR) = [fasting insulin (uU/ml) × fasting glucose
(mmol/L)] / 22.5. Insulin resistance is defined as the levels
of the homeostasis model assessment for insulin resistance
(HOMA-IR) greater than 3.16 [13,14].Estimation of serum 25 (OH) D levels
Samples for serum vitamin D level estimation were
collected in heparinized amber colored glass vials to
prevent photo degradation. Serum was extracted after
centrifugation and then stored at–20°C until analyzed. In
those who presented with ketoacidosis, samples were taken
4–5 days after normalization of pH.
Serum 25(OH)D level was measured by 25(OH) vitamin
D ELISA assay kit (Eagle Biosciences, Inc.USA) according
to the manufacturer’s instructions, to each well it was
added 200 μl of prediluted serum sample, control or
standard separately and incubated for 2 hours at 25°C,
after washing, 100 μl of Enzyme Conjugate was added into
each well and incubate for 30 min at room temperature,
then, after washing, 100 μl of chromogen/ substrate solu-
tion was added into each well and incubated for 15 minutes
at room temperature without shaking (protected from
direct sunlight). Finally, 100 μl of stop solution was added
to each well, and absorbance was read at 450 nm.
Vitamin D status was classified according to the American
Academy of Pediatrics (AAP)/LWEPS’s recommendations
on cut-off levels for states of vitamin D. A 25(OH)D level
of <5 ng/mL (<12.5 nmol/L) was considered as severe defi-
ciency, a level between 5 and 15 ng/mL (12.5-37.5 nmol/L)
as deficiency, a level of 15–20 ng/mL (37.5-50 nmol/L) as
insufficiency, and a level of 20–100 ng/mL (50–250 nmol/L)
as normal (sufficient) [15]. Our patients were also divided
into 2 groups according to their vitamin D status. Those
with serum 25(OH) D levels <20 ng/mL were grouped as
vitamin D insufficient and deficient, and those with serum
25(OH) D levels >20 ng/mL as normal with regard to
vitamin D status [15].
Serum level of ALP and fasting blood glucose level were
measured using a Dimension XL auto analyzer (Siemens,
German).Estimation of serum PTH and serum insulin level
Serum parathyroid hormone (PTH) and serum insulin were
measured by electrochemiluminescence immunoassay using
Cobas e 411 immunoassay analyzer (Roch Diagnostics,
GmbH, German). The manufacturer’s normal range for
PTH was 15–65 pg/ml. Secondary hyperparathyroidism
was defined as a PTH level greater than 65 pg/mL. HbA1c
levels were measured by affinity chromatography test using
(biosystem kit-USA) in which the affinity gel columns were
used to separate glycated hemoglobin which binds to the
column.Ethics
Informed parental consent was obtained to be eligible for
enrollment into the study. The study was done according
to the rules of the Local Ethics Committee of Faculty of
Medicine, Zagazig University, Egypt.
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SPSS version 19 was used for data analysis. The data are
expressed as the mean ± SD or median (min-max) where
appropriate. Test selection was based on evaluating the
variables for normal distribution using the Shapiro-Wilk
test. If the variables had a normal distribution, Student's
t-test was used. If the variable did not have a normal dis-
tribution, the analysis was done using the Mann–Whitney
U test. Categorical data were evaluated by Pearson's chi-
square test. The correlations between variables were
performed by Pearson’s Correlation test. P < 0.05 was con-
sidered significant.
Results
There was no significant difference between diabetic
cases and control group as regards age, gender, or BMI
(P > 0.05), respectively (Table 1). Median disease duration
in our diabetic cases was 17 months (range 3–52 months)
(Table 1).
Our data showed that 44(55%) diabetic cases were
vitamin D deficient; meanwhile 36(45%) cases had normal
vitamin D level. On the other hand, 12(30%) of the control
group, were vitamin D deficient and 28(70%) had normal
serum vitamin D level (P < 0.01; Figure 1).
Of note, 26(32.5%) diabetic cases had 2ry hyperpara-
thyroidism and 54(67.5%) cases had normal parathyroid
hormone level; meanwhile, none of the control group
had 2ry hyperparathyroidism (P < 0.01; Figure 2).
Serum calcium level was significantly lower in diabetic
cases (8.5 ± 1.6 mg/dL) compared to the control group
(10 ± 1.4 mg/dL; P < 0.01), respectively (Table 2). Mean-
while, serum phosphorus, parathyroid hormone and fasting
blood glucose levels were significantly higher in diabetic
cases compared to the control group (all P < 0.01). How-
ever, no significant difference was observed between both
groups as regards to serum vitamin D level (24.7 ± 5.6 vs
26.5 ± 4.8 ng/ml; P > 0.05) (Table 2).
A significant difference was observed between vitamin
D deficient diabetic cases and those with normal vitamin
D level regarding serum calcium, phosphorus, alkaline
phosphatase, and serum parathyroid hormone levels
(all P < 0.01). Moreover, vitamin D deficient diabetic casesTable 1 Demographic data of studied subjects
Cases (n = 80) Control (n = 40) P
Male/female # 34/46 24/16 > 0.05
Age (years) 11.4 ± 2.5 10.8 ± 2.3 > 0.05
BMI (kg/m2) 23.6 ± 5.7 21.8 ± 4.7 > 0.05
Disease duration (months) 17 (3–52) - -
BMI, body mass index.
Data are presented as mean ± SD or median (min-max).
Student t-test was used for comparisons. P value < 0.05 indicates a
significant difference.
# Chi-square test.had significantly higher HOMA-IR values than those with
normal vitamin D level (4.7 ± 0.3 Vs 2.8 ± 0.6; P < 0.01). Of
note, we observed significantly shorter disease duration
in vitamin D deficient diabetic cases compared to those
with normal vitamin D level (6.7 ± 2.3 Vs 43 ± 9 months;
P < 0.01), respectively (Table 3).
In diabetic cases, serum levels of vitamin D showed
significant negative correlations with BMI (r = −0.643,
P < 0.01; Table 4), meanwhile it showed significant positive
correlations with disease duration (r = 0.544, P < 0.01;
Table 4) .On the other hand, serum levels of vitamin D did
not correlate with clinical parameters, such as age, gender;
or with biochemical parameters, such as serum calcium,
phosphorus, alkaline phosphatase, fasting blood glucose,
HbA1C or HOMA-IR (all P > 0.05; Table 4).Discussion
As vitamin D deficiency is considered to be directly
involved in inducing immune-mediated β-cell destruction
as well as calcium mediated dysfunction leading to onset
of clinical Diabetes, the levels of vitamin D must be low at
the time of diagnosis. Some previous studies did show that
vitamin D levels are low at the time of diagnosis [16,17].
The nationwide Diabetes Incidence Study in Sweden
(DISS) found that the 25 OHD levels in the new onset
T1D (n = 459) were low compared to controls (P < 0.001).
The vitamin D levels were also low after 8 yr of follow up
in T1D [16].
In the present study, we found that serum vitamin D
levels were not significantly lower in diabetic subjects com-
pared to the control group (24.7 ± 5.6 vs 26.5 ± 4.8 ng/ml;
P > 0.05).
These results are different from those of Pozzili et al.
who found that the 25(OH) D levels in new onset T1D
(n = 88) were low compared to healthy controls (P < 0.01).
They also studied the correlation between vitamin D and
time when diagnosis was made and concluded that vitamin
D levels were similarly low during summer and winter
months, excluding the possibility of a significant seasonal
variation [17].
There are two main biochemical parameters regarding
the negative effects of vitamin D deficiency on the skeleton
namely ALP and iPTH. The cut-off point of serum 25-
OHD in which the mean serum PTH concentration
begins to increase is defined as 20 or 30 ng/ml [18].
In our study, we found that serum calcium was signifi-
cantly lower and both serum phosphorus and serum
parathyroid hormone were significantly higher in dia-
betic subjects compared to control children (all P <
0.01).
This agreed with a study performed by Hamed et al who
revealed that serum PTH levels were significantly higher




















Figure 1 Vitamin D status among studied subjects.
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functioning feedback mechanisms to the decrease in
serum levels of calcium and 25(OH) D [19].
By contrast, Kemink et al demonstrated normal or even
low PTH concentrations in diabetic patients [20].
Our results showed a significant negative correlation
between serum vitamin D and BMI (r = −0. 643, p < 0.01).
This was concordant with the results of the 2001–2004
National Nutrition and Health Survey in the United States
indicate that metabolic syndrome prevalence was 3.8 fold
higher among obese adolescents whose 25(OH) D levels
were lower than 15 ng/mL as compared to those with
levels higher than 26 ng/mL [21].
On the other hand, Çizmecioglu et al found that vitamin
D deficiency and insufficiency are common in obese and
overweight schoolchildren, especially in girls. Obesity could
be a risk factor in terms of hypovitaminosis D in adoles-
cents. Vitamin D supplementation should be administered
particularly to adolescent girls [22].
Previous cohort studies explained that lower serum 25


















Figure 2 Parathyroid hormone status among studied subjects.higher iPTH concentrations; and serum iPTH levels were
positively correlated with the degree of adiposity and were
higher only in the hypovitaminosis D and vitamin D–defi-
cient groups compared with the vitamin D–sufficient
subjects [23,24].
In the present study, we found a significant difference
between vitamin D deficient cases and those with normal
vitamin D level regarding HOMA-IR (4.7 ± 0.3 Vs 2.8 ± 0.6;
P < 0.01) and diabetes duration (6.7 ± 2.3 Vs 43 ± 9 months;
P < 0.01), meanwhile no significant difference was observed
as regards HbA1c (P > 0.05).
This was concordant with Chiu et al who observed a
positive relationship between vitamin D status and insu-
lin sensitivity index in adults. In addition, they showed
that vitamin D levels were negatively correlated with
both first- and second phase insulin responses during a
hyperglycemic clamp and glucose levels during oral glu-
cose tolerance test. Thus, they suggested that subjects
with hypovitaminosis D not only displayed impaired β-cell
function causing impaired glucose homeostasis, but also
were at increased risk of developing insulin resistance and00%
ol




 subjects with normal
parathyroid hormone
level
Table 2 Laboratory data of studied subjects
Cases Control P
(n = 80) (n = 40)
Serum Ca (mg/dL) 8.5 ± 1.6 10 ±1.4 <0.01a
Serum Po4 (mg/dL) 5.4 ± 1.5 3.6 ± 0.9 <0.01a
Serum Alkaline
phosphatase (IU/L)
200(44–453) 189(68–451) > 0.05b
Fasting blood Glucose (mg/dL) 178(112–316) 94(80–133) <0.01b
Fasting insulin (uU/mL) 5.2 ± 1.9 6.7 ± 2.3 < 0.05a
Insulin dose (U/Kg/d) 0.9 ± 0.1 -
HbA1c (%) 8.6 ± 1.9 -
HOMA-IR 3.5 ± 0.7 1.4 ± 0.3 <0.01a
Serum 25 OH Vit D (ng/ml) 24.7 ± 5.6 26.5 ± 4.8 > 0.05a
Serum PTH (pg/ml) 57.7 ± 13.2 33.3 ± 8.3 <0.01a
HbA1c: glycosylated hemoglobin; HOMA-IR: Homeostasis model for assessment
of insulin resistance; Serum PTH: serum parathyroid hormone.
Data are presented as mean ± SD or median (min-max).
P value < 0.05 indicates a significant difference.
a(Student t-test). b Mann–Whitney U test.
Table 4 Correlation between serum vitamin D levels and
clinic-laboratory parameters in diabetic children
Vitamin D vs. r P value
Age (years) 0.213 > 0.05
Gender 0.168 > 0.05
BMI (kg/m2) −0.643 <0.01
Serum Ca (mg/dL) 0.285 > 0.05
Serum Po4 (mg/dL) −0.196 > 0.05
Serum Alkaline phosphatase (IU/L) −0.113 > 0.05
Fasting blood Glucose (mg/dL) −0.186 > 0.05
HbA1c (%) −0.175 > 0.05
HOMA-IR −0.209 > 0.05
Disease duration (months) 0.544 <0.01
BMI: body mass index; HbA1c: glycosylated hemoglobin; HOMA-IR: Homeostasis
model for assessment of insulin resistance.
(Pearson’s Correlation analysis).
P value < 0.05 indicates a significant difference.
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subjects [25].
On the other hand, previous studies showed that
serum 25(OH) D levels were inversely correlated with
HbA1c independent of body fat, implying higher ambient
glucose concentrations in children with lower vitamin D
concentrations [26,27].
In our study, no significant difference was observed









Serum Ca (mg/dL) 7.3 ± 1.0 9.6 ± 1.1 <0.01a
Serum Po4 (mg/dL) 6.1 ± 1.4 4.4 ± 1.0 <0.01a
Serum alkaline
phosphatase (IU/L)
260 (44–453) 128 (66–251) <0.01b
Serum PTH (pg/ml) 66.1 ± 9.4 47.4 ± 9.3 <0.01a
Fasting blood
Glucose (mg/dL)>
208 (115–316) 197 (112–282) 0.05b
Fasting insulin (uU/mL) 6.7 ± 1.5 7.2 ± 1.2 > 0.05a
Insulin dose (U/Kg/d) 0.93 ± 0.11 0.91 ± 0.18 > 0.05a
HbA1c (%) 9.0 ± 1.6 8.4 ± 2.1 > 0.05a
HOMA-IR .7 ± 0.3 42.8 ± 0.6 <0.01a
Disease duration
(months)
6.7 ± 2.3 43 ± 9 <0.01a
Serum PTH: serum parathyroid hormone; HbA1c: glycosylated hemoglobin;
HOMA-IR: Homeostasis model for assessment of insulin resistance.
Data are presented as mean ± SD or median (min-max). P value < 0.05
indicates a significant difference. a(Student t-test). b MannWhitney U test.vitamin D level regarding fasting blood glucose and fasting
insulin levels (P > 0.05).
These results are concordant with those of a recent
report by Erdonmez et al who found that no correlations
were found between insulin measurements during oral
glucose tolerance test and vitamin D deficiency. They added
that mean vitamin D levels were similar in subjects with
and without metabolic syndrome (P > 0.05) [28].
On the other hand, another study conducted among
adolescents of French origin in Canada failed to reveal an
association between 25(OH) D level and existence of at
least two components of metabolic syndrome. In the same
study, it was shown that every 10 ng/mL increment in 25
(OH) D levels causes a mild decrease in the fasting blood
glucose levels and HOMA- IR [29].
Our data showed a significant difference between
vitamin D deficient cases and those with normal vita-
min D level regarding serum calcium, phosphorus, al-
kaline phosphatase, serum parathyroid hormone levels
(all P < 0.01); which confirm the results of previous
studies [30,31].
Although our data revealed that vitamin D defi-
ciency were more common among diabetic children
compared to the control group (P < 0.01),our study
failed to find a significant difference between diabetic
children and healthy controls as regards serum vita-
min D levels (P > 0.05).
The small sample size was one of our limitations in
this study; we suggest that multicenter approaches may
be necessary to attain larger sample sizes. Future longi-
tudinal cohort studies are recommended to better inves-
tigate the correlations assessed in the present study and
to evaluate the effects of time on the analyzed variables.
Finally, more extended studies to define the role of
vitamin D in the pathogenesis of type 1 diabetes are
Azab et al. Italian Journal of Pediatrics 2013, 39:73 Page 6 of 7
http://www.ijponline.net/content/39/1/73urgently needed because trials using active form of this
metabolite for type 1 diabetes prevention are actively be-
ing considered.
Conclusion
Public health message on the importance of vitamin D
status; especially in diabetic children and adolescents,
should be disseminated to the public.
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